Should You Buy Summit Therapeutics Inc (SMMT) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
15.400
1 Day change
-1.53%
52 Week Range
36.910
Analysis Updated At
2026/01/26
Summit Therapeutics Inc (SMMT) is not a strong buy for a beginner, long-term investor at this moment. The technical indicators show a bearish trend, options data suggests mixed sentiment, and the financial performance is weak with significant losses. While there is a slight positive from the analyst upgrade, there are no strong catalysts or signals to justify immediate investment.
Technical Analysis
The MACD is negative and expanding, RSI is neutral at 39.964, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 15.963 and resistance at 17.696.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The open interest put-call ratio indicates slightly bearish sentiment, while the option volume put-call ratio suggests more call activity, which could indicate speculative bullishness.
Technical Summary
Sell
10
Buy
4
Positive Catalysts
Barclays upgraded the stock to Equal Weight with a price target of $18, citing potential in lung cancer updates in 2026 and opportunities in other tumor types.
Neutral/Negative Catalysts
Wolfe Research expressed skepticism about the Harmoni-2 trial's overall survival benefit. No recent news or significant insider/hedge fund activity. Financial performance shows substantial losses.
Financial Performance
In Q3 2025, revenue remained at $0 with no growth. Net income was -$231.79M, improving by 312.05% YoY but still deeply negative. EPS improved to -0.31, up 287.50% YoY, but remains in the red.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Barclays upgraded the stock to Equal Weight with a price target increase to $18 from $16. Wolfe Research initiated coverage with a Peer Perform rating, expressing doubts about the success of the Harmoni-2 trial.
Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 42.49 USD with a low forecast of 18 USD and a high forecast of 131.9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 42.49 USD with a low forecast of 18 USD and a high forecast of 131.9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 15.640
Low
18
Averages
42.49
High
131.9
Current: 15.640
Low
18
Averages
42.49
High
131.9
Barclays
Underweight -> Equal Weight
upgrade
$16 -> $18
AI Analysis
2025-12-17
Reason
Barclays
Price Target
$16 -> $18
AI Analysis
2025-12-17
upgrade
Underweight -> Equal Weight
Reason
Barclays upgraded Summit Therapeutics to Equal Weight from Underweight with a price target of $18, up from $16. The firm believes the company's lung cancer updates in 2026 "will be meaningful." It sees multiple upcoming opportunities for Summit in different tumor types.
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Summit Therapeutics with a Peer Perform rating and no price target. The firm's analysis suggests the Harmoni-2 may not show an overall survival benefit, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SMMT
